According to The New England Journal of Medicine, investigators at Uppsala University Hospital implanted a product called ...
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Tessera Therapeutics secures $150M from Regeneron to develop gene therapy for AATD, a genetic condition affecting the lungs ...
Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.
3h
Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder
Regeneron and Tessera partner on TSRA-196, a one-time gene writing therapy targeting alpha-1 antitrypsin deficiency with FDA ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...
Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have announced a global collaboration to develop and ...
The field of in vitro modeling of organogenesis and disease has witnessed remarkable progress due to innovations in stem cell ...
Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date/time: Monday, ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...
As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...
19h
Lyme disease often goes undetected when it's most treatable. These teens are working to change that.
Teens at a Georgia high school may have come up with a better way to detect and treat Lyme disease. They took their idea to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback